• Roche Global
  • Roche New Zealand
Roche
Roche
  • Home
  • Cancer Type
    • Breast Cancer
      • Symptoms & Diagnosis
      • Standard Treatments
      • Targeted Therapies
      • Sources of Further Information
    • Bowel Cancer
      • Symptoms and Diagnosis
      • Standard Treatments
      • Targeted Therapies
      • Sources of Further Information
    • Skin Cancer
      • Symptoms and Diagnosis
      • Standard Treatments
      • Targeted Therapies
      • Sources of Further Information
    • Blood Cancer
      • Symptoms and Diagnosis
      • Standard Treatments
      • Targeted Therapies
      • Sources of Further Information
    • Lung Cancer
      • Symptoms and Diagnosis
      • Standard treatments
      • Targeted Therapies
      • Sources of Further Information
    • Cervical Cancer
      • Symptoms and Diagnosis
      • Standard Treatments
      • Targeted Therapies
      • Sources of Further Information
    • Ovarian Cancer
      • Symptoms and Diagnosis
      • Standard Treatments
      • Targeted Therapies
      • Sources of Further Information
    • Brain Cancer
      • Symptoms and Diagnosis
      • Standard Treatments
      • Targeted Therapies
      • Sources of Further Information
    • Stomach Cancer
      • Symptoms and Diagnosis
      • Standard Treatments
      • Targeted Therapies
      • Sources of Further Information
  • Treatments
    • Avastin
      • Avastin for Brain Cancer
      • Avastin for Bowel Cancer
      • Avastin for Cervical Cancer
      • Avastin for Lung Cancer
      • Avastin for Ovarian Cancer
    • Gazyva
      • Gazyva for First-Line Chronic Lymphocytic Leukaemia
    • Herceptin
      • Herceptin for Early Breast Cancer
      • Herceptin for Metastatic Breast Cancer
      • Herceptin for Stomach Cancer
    • Kadcyla
      • Kadcyla for Metastatic Breast Cancer
    • MabThera
      • MabThera for Second-Line or Relapsed Chronic Lymphocytic Leukaemia
      • MabThera as a Maintenance Treatment for Follicular Lymphoma
    • Perjeta
      • Perjeta for Early Breast Cancer
      • Perjeta for Metastatic Breast Cancer
    • Tarceva
      • Tarceva for Lung Cancer
    • TECENTRIQ
      • TECENTRIQ for Lung Cancer
    • Zelboraf
      • Zelboraf for Skin Cancer
  • Accessing Treatment
    • Funding and Cost Share Programmes
    • Private Providers
    • Understand how Medicines are Made Available for Kiwis
  • Latest Articles
    • Foundation Medicine
    • Metastatic Melanoma - do you know all your options?
    • Breast Cancer in New Zealand
    • Understanding how medicines are made available to New Zealanders
    • Targeted treatment options bring new hope to cancer patients
    • New multi-medicine agreement with Pharmac
    • What you need to know about bowel cancer
    • New private cancer clinic opened in Tauranga
    • First Private Cancer Care Centre Opens In Wellington
    • If you have early breast cancer, this is important news for you.
Roche
  • Home
  • Cancer Type
    • Breast Cancer
      • Symptoms & Diagnosis
      • Standard Treatments
      • Targeted Therapies
      • Sources of Further Information
    • Bowel Cancer
      • Symptoms and Diagnosis
      • Standard Treatments
      • Targeted Therapies
      • Sources of Further Information
    • Skin Cancer
      • Symptoms and Diagnosis
      • Standard Treatments
      • Targeted Therapies
      • Sources of Further Information
    • Blood Cancer
      • Symptoms and Diagnosis
      • Standard Treatments
      • Targeted Therapies
      • Sources of Further Information
    • Lung Cancer
      • Symptoms and Diagnosis
      • Standard treatments
      • Targeted Therapies
      • Sources of Further Information
    • Cervical Cancer
      • Symptoms and Diagnosis
      • Standard Treatments
      • Targeted Therapies
      • Sources of Further Information
    • Ovarian Cancer
      • Symptoms and Diagnosis
      • Standard Treatments
      • Targeted Therapies
      • Sources of Further Information
    • Brain Cancer
      • Symptoms and Diagnosis
      • Standard Treatments
      • Targeted Therapies
      • Sources of Further Information
    • Stomach Cancer
      • Symptoms and Diagnosis
      • Standard Treatments
      • Targeted Therapies
      • Sources of Further Information
  • Treatments
    • Avastin
      • Avastin for Brain Cancer
      • Avastin for Bowel Cancer
      • Avastin for Cervical Cancer
      • Avastin for Lung Cancer
      • Avastin for Ovarian Cancer
    • Gazyva
      • Gazyva for First-Line Chronic Lymphocytic Leukaemia
    • Herceptin
      • Herceptin for Early Breast Cancer
      • Herceptin for Metastatic Breast Cancer
      • Herceptin for Stomach Cancer
    • Kadcyla
      • Kadcyla for Metastatic Breast Cancer
    • MabThera
      • MabThera for Second-Line or Relapsed Chronic Lymphocytic Leukaemia
      • MabThera as a Maintenance Treatment for Follicular Lymphoma
    • Perjeta
      • Perjeta for Early Breast Cancer
      • Perjeta for Metastatic Breast Cancer
    • Tarceva
      • Tarceva for Lung Cancer
    • TECENTRIQ
      • TECENTRIQ for Lung Cancer
    • Zelboraf
      • Zelboraf for Skin Cancer
  • Accessing Treatment
    • Funding and Cost Share Programmes
    • Private Providers
    • Understand how Medicines are Made Available for Kiwis
  • Latest Articles
    • Foundation Medicine
    • Metastatic Melanoma - do you know all your options?
    • Breast Cancer in New Zealand
    • Understanding how medicines are made available to New Zealanders
    • Targeted treatment options bring new hope to cancer patients
    • New multi-medicine agreement with Pharmac
    • What you need to know about bowel cancer
    • New private cancer clinic opened in Tauranga
    • First Private Cancer Care Centre Opens In Wellington
    • If you have early breast cancer, this is important news for you.
News Articles
You are here: Home / News Articles
News Articles News article 1 News article 2 Media Release
  • Roche Global
  • Roche New Zealand
  • Privacy Statement
  • Legal Statement

© 2017 Roche Products (New Zealand) Limited. For more information please visit www.medsafe.govt.nz. Access to this site is subject to the terms in our Legal Statement. You accept these terms by continuing to access this site. This site was last updated on March 2016. ID2231/TAPS NA8256/2016MAR. Spitfire J000084